Last reviewed · How we verify

NCT07056738

Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients

ENROLLING BY INVITATION Last updated 9 July 2025
What this trial tests

trial testing imaging in Retinitis Pigmentosa in 130 participants. Enrolling by invitation.

Timeline
1 March 2025
Primary endpoint
1 March 2030
1 April 2030

Quick facts

Lead sponsorUniversity Medical Center Goettingen
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment130
Start date1 March 2025
Primary completion1 March 2030
Estimated completion1 April 2030
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Medical Center Goettingen

Who can join

18 and older, any sex, with Retinitis Pigmentosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is an explorative prospective observation of retinal ganglion cell degeneration and/or inner retina degeneration in Retinitis pigmentosa patients. The rate and patterns of progression will be correlated to the outer retina layers as well as clinical and genetic data of patients. Secondary goal is to determine potential parameters for optogenetic treatment eligibility.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of imaging

Trials testing the same drug.

Other recruiting trials for Retinitis Pigmentosa

Currently open trials in the same condition.

Other University Medical Center Goettingen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07056738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing